Economic impact of migraine and other episodic headaches in France: Data from the GRIM2000 study

PharmacoEconomics

Volumn 22, Issue 15, 2004, Pages 985-999

  Pradalier, André ^a   Auray, Jean Paul ^b   El Hasnaoui, Abdelkader ^c   Alzahouri, Kazem ^b   Dartigues, Jean François ^d   Duru, Gérard ^b   Henry, Patrick ^e   Lantéri Minet, Michel ^f   Lucas, Christian ^g   Ghazot, Guy ^h   Gaudin, Anne François ^c  

^a HÔPITAL LOUIS MOURIER   (France)

^b UNIVERSITÉ LYON 1   (France)

^c GLAXOSMITHKLINE   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e HÔPITAL PELLEGRIN   (France)

^f PASTEUR HOSPITAL   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ERGOT ALKALOID; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ABSENTEEISM; ADOLESCENT; ADULT; ALTERNATIVE MEDICINE; ARTICLE; CONSULTATION; CONTROLLED STUDY; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; EPISODIC HEADACHE; FRANCE; HEADACHE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; INTERVIEW; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL FEE; MIGRAINE; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; QUESTIONNAIRE; SELF MEDICATION;

EID: 8144228242     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422150-00003     Document Type: Article

References (37)

1. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998; 13: 667-76
2. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994; 28: 659-964
3. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67-76
4. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29-35
5. Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992; 32: 223-8
6. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131-7
7. Michel P, Auray JP, Chicoye A, et al. Prise en charge des migraineux en France: coût et recours aux soins: évaluation économique de la migraine en France. J Econ Med 1993; 11: 71-80
8. Kryst S, Scherl E. A population-based survey if the social and personal impact of headache. Headache 1994; 34: 344-50
9. Lipton RB, Stewart WF, Celentano DD, et al. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992; 152: 1273-8
10. Stang PE, Osterhaus JT, Celentano DD. Migraine: patterns of healthcare use. Neurology 1994; 44: S47-55
11. Michel P, Pariente P, Duru G, et al. A population-based, nationwide, comparative survey of access to care in migraine in France. Cephalalgia 1996; 16: 50-5
12. Michel P, Dartigues JF, Lindoulsi A, et al. Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache 1997; 37: 71-8
13. Michel P, Dartigues JF, Duru G, et al. Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia 1999; 19: 503-10
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
15. Bateman DN. Triptans and migraine. Lancet 2000; 335: 860-1
16. Leff RF, Sclar DA, Nemec NL. Cost-effectiveness of sumatriptan in a managed care population. Am J Manag Care 1997; 3: 117-22
17. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 1996; 36: 538-41
18. Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. Neurology 2002; 59: 232-7
19. Richard A, Henry P, Chazot G, et al. Qualité de vie et migraine: validation du questionnaire QVM en consultation hospitalière et en médecine générale. Thérapie 1993; 48: 89-96
20. Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53: 988-94
21. El Hasnaoui A, Vray M, Richard A, et al. Assessing the severity of migraine: development of the MIGSEV scale. Headache 2003 Jun; 43 (6): 628-35
22. Vidal, Louis. Dictionnaire Vidal 1999. Paris: Paris Office De Vulgarisation Pharmaceutique, 1999
23. UCANSS [online]. Available from URL: http://www.ucanss.fr/ ucanss.nsf/ [Accessed 2004 Aug 25]
24. Lantéri-Minet M, Auray JP, El Hasnaoui A, et al. Prevalence and description of chronic daily headache in the general population in France. Pain 2003; 2: 143-9
25. Lantéri-Minet M, Lucas C, Chaffaut C. Comportements thérapeutiques des migraineux: Framig 2000 II. Douleur 2001; 2: 233-46
26. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. JAMA 1992; 267: 64-9
27. Van Roijen L, Essink-Bot ML, Koopmanschap MA, et al. Societal perspective on the burden of migraine in the Netherlands. Pharmacoeconomics 1995; 7: 170-9
28. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159: 812-8
29. Björk S. Roos P. Economic aspects of migraine in Sweden. Lund: Institute for Health Economics, 1991
30. Blau JN, Drummond MF, editors. Migraine. London: Office of Health Economics, 1991
31. Parry TG. The prevalence and costs of migraine in Australia. Centre for Applied Economic Research (CAER) working paper n° 1992/1 Kensingyon: University of New South Wales. 1992.
32. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638-45
33. Reynaud M, Gaudin-Colombel AF, Le Pen C. Two methods of estimating health costs linked to alcoholism in France (with a note on social costs). Alcohol Alcohol 2001; 36: 89-95
34. Boyer P, Dardennes R, Even C, et al. Dépression et santé publique: données et réflexions. Paris: Masson, 1999, 117
35. Jönsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002; 45: S5-S12
36. Thirouin I. Allergie respiratoire, asthme, environnement: un programme pluriannuel de santé publique. Echanges Santé Social 1994: 74
37. Lipton RB, Silberstein SD. The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology 2001; 56 Suppl. 1: S35-42